Compare BGLC & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | EVGN |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 9.9M |
| IPO Year | N/A | N/A |
| Metric | BGLC | EVGN |
|---|---|---|
| Price | $3.05 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 8.0K | ★ 49.2K |
| Earning Date | 11-14-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,465,006.00 | $8,016,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.21 | ★ 7.19 |
| 52 Week Low | $2.01 | $0.93 |
| 52 Week High | $15.60 | $2.42 |
| Indicator | BGLC | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 23.39 | 49.26 |
| Support Level | $3.02 | $1.00 |
| Resistance Level | $3.52 | $1.08 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 35.29 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.